Pharmacological properties of (+)-buprenorphine and (+)-diprenorphine.
Grayson
N A
NA
Laboratory of Medicinal Chemistry, NIDDK, National Institutes of Health, Bethesda, MD 20892.
Rothman
R B
RB
Xu
H
H
Rice
K C
KC
D000818:Animals; D002047:Buprenorphine / Q000494:pharmacology*; D003042:Cocaine / Q000494:pharmacology*; D004174:Diprenorphine / Q000494:pharmacology*; D006168:Guinea Pigs; D066298:In Vitro Techniques; D051381:Rats; D011957:Receptors, Opioid / Q000378:metabolism; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D012646:Self Administration / Q000523:psychology
D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D004174:Diprenorphine; D002047:Buprenorphine; D003042:Cocaine